Samuel Saks

Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT.

Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA

Auspex Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of novel medicines for the treatment of orphan diseases. The company was founded by Sepehr Sarshar, Thomas G. Gant and Manouchehr M. Shahbaz on February 28, 2001 and is headquartered in San Diego, CA.

Qwell Pharmaceuticals, Inc. developed small molecule drugs for oncology indications. It was a start-up biotechnology company devoted to small-molecule development derived from a plant source that have a potent ability to fight tumors and excess inflammation of skin cells. The company was founded in 2008 and was headquartered in Seattle, WA.

Bullet Biotechnology, Inc. develops active immunotherapies to stimulate a person’s own immune system to overcome diseases. Its technology educates the immune system to targeting specific cells that are causing disease. The firm's pipeline includes therapeutic vaccines for cancer, multi-specific antibody capsid products, therapeutic vaccines for autoimmune diseases, and other vaccines. The company was founded by Diego Fonstad, James R. Swartz, Willie Quinn and Thomas Theriault in September 2011 and is headquartered in Redwood City, CA.

Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA.

Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

NuMedii, Inc. discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies. Its Big Data technology, originally developed at Stanford University, utilizes large amounts of scientific data together with proprietary biological network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. The firm translates these predictions into novel de-risked drug candidates and partners with pharmaceutical companies for development and commercialization. The company was founded by Gini Deshpande, Joel Dudley and Atul J. Butte in 2008 and is headquartered in Palo Alto, CA.

PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV.

Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics.

Ilypsa, Inc. operates a biopharmaceutical firm. It develops renal care pharmaceutical products. The company was founded on March 6, 2003 and is headquartered in Thousand Oaks, CA.

Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA.

Hinge Bio, Inc. is a holding company, which engages in the development of specific and multi-specific antibodies. The company is headquartered in Burlingame, CA.

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

Quanta Therapeutics, Inc. develops biotechnologies. The American company was founded in 2018 by Cameron Pitt, Frank McCormick. Perry D. Nisen has been the CEO of the company since 2021.